Study on the Response to Tetanus Vaccination of People Living With HIV
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Centre Hospitalier de Niort
- Enrollment
- 210
- Locations
- 2
- Primary Endpoint
- the vaccine response to tetanus vaccination
Study Overview
Brief Summary
The response to primary tetanus immunization of HIV-infected children is lower than that of uninfected children.
Response to tetanus toxoid (TT) booster doses in adults living with HIV who have received primary vaccination prior to infection is not known.
Currently, it is recommended to have a TT booster for people living with HIV (PLHIV) every 10 years. In general population, this recall is made only at 25, 45 and 65 years, then every 10 years.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Person aged ≥ 18 years
- •Person infected with HIV followed in the infectious diseases department of CH Niort
- •Born in France
- •Affiliate or beneficiary of a social security scheme
- •Being able to give free and informed consent to participation in research
Exclusion Criteria
- •Persons with a contraindication to tetanus vaccination
- •Persons under guardianship or curatorship or without civil law
Outcomes
Primary Outcomes
the vaccine response to tetanus vaccination
Time Frame: Month 6
An anti-tetanus IgG level\> 0.1 is considered long-term protective. An anti-tetanus IgG level between 0.01 and 0.1 is considered protective in the short term. The measurement of the vaccine response will be correlated with the age of the last VAT recall (\<10 years, between 10 and 20 years,\> 20 years and unknown)
Secondary Outcomes
No secondary outcomes reported